Nisa Investment Advisors LLC Sells 19,162 Shares of Illumina, Inc. (NASDAQ:ILMN)

Nisa Investment Advisors LLC reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 78.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,234 shares of the life sciences company’s stock after selling 19,162 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Illumina were worth $415,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in ILMN. Capital World Investors grew its stake in shares of Illumina by 408.6% during the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company’s stock valued at $2,408,721,000 after purchasing an additional 14,481,232 shares during the period. Brown Advisory Inc. grew its stake in shares of Illumina by 54,220.9% during the 4th quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company’s stock valued at $255,586,000 after purchasing an additional 1,909,118 shares during the period. Norges Bank bought a new stake in shares of Illumina during the 4th quarter valued at about $228,714,000. Bessemer Group Inc. grew its stake in shares of Illumina by 32,837.5% during the 4th quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company’s stock valued at $180,152,000 after purchasing an additional 1,344,038 shares during the period. Finally, Assenagon Asset Management S.A. grew its stake in shares of Illumina by 2,057.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 922,281 shares of the life sciences company’s stock valued at $73,174,000 after purchasing an additional 879,533 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Illumina Trading Down 0.2%

Shares of Illumina stock opened at $96.96 on Thursday. The firm has a market cap of $15.35 billion, a price-to-earnings ratio of -15.97, a PEG ratio of 1.91 and a beta of 1.36. The business has a 50-day moving average price of $88.45 and a 200-day moving average price of $95.70. The company has a quick ratio of 1.48, a current ratio of 1.86 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.01. The firm had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The business’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.98 earnings per share. Equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on ILMN. Guggenheim reduced their price target on Illumina from $122.00 to $114.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Evercore ISI upped their price target on Illumina from $116.00 to $128.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. Citigroup cut Illumina from a “hold” rating to a “strong sell” rating and reduced their price target for the stock from $85.00 to $80.00 in a research report on Wednesday, July 9th. Barclays restated an “underweight” rating and issued a $85.00 price target (up previously from $77.00) on shares of Illumina in a research report on Tuesday, June 24th. Finally, JPMorgan Chase & Co. reduced their price target on Illumina from $120.00 to $85.00 and set a “neutral” rating for the company in a research report on Friday, May 9th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Illumina has an average rating of “Hold” and an average target price of $125.11.

Insider Activity

In other Illumina news, CFO Ankur Dhingra bought 6,100 shares of the firm’s stock in a transaction dated Monday, May 12th. The shares were purchased at an average cost of $81.21 per share, for a total transaction of $495,381.00. Following the transaction, the chief financial officer owned 24,906 shares of the company’s stock, valued at $2,022,616.26. This represents a 32.44% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.60% of the company’s stock.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.